Avalo Therapeutics (AVTX) Stock: Buy, Sell, or Hold?
AVTX - Avalo Therapeutics, Inc. Common Stock
$14.99
0.04 (0.27%)
▲
5d:
-3.1%
30d:
-22.49%
90d:
-24.9%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
30d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 25, 2026 at $15.47 · last confirmed Oct 2, 2026
Strength: 9.0/10
Get Alerted When AVTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AVTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: AVTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: AVTX is currently trading at $14.99, which is considered oversold relative to its 30-day fair value range of $15.54 to $19.19.
Technical Outlook: Technically, AVTX is in a uptrend. Immediate support is located at $14.31, while resistance sits at $16.86.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $44.08 (+194.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AVTX is in a uptrend. Immediate support is located at $14.31, while resistance sits at $16.86.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $44.08 (+194.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$15.54 -
$19.19
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (53/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 194.1% below Wall St target ($44.08)
- NEUTRAL: Bottoming setup forming (53/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$15.54 -
$19.19
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$14.31
Resistance Level
$16.87
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.47
Wall Street Target
$44.08
(+194.1%)
Revenue Growth (YoY)
-69.3%
Share & Embed Analysis
Last updated: October 05, 2026 8:36 AM ET
Data refreshes hourly during market hours. Next update: 9:36 AM
Data refreshes hourly during market hours. Next update: 9:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$109 | 76 BUY |
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
27 analysts |
$92 | 46 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$285 | 42 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
16 analysts |
$141 | 63 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$128 | 56 HOLD |
